Chalcone-inspired rA1/A2A adenosine receptor ligands: Ring closure as an alternative to a reactive substructure
- 1 March 2022
- journal article
- research article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 99 (3) , 416-437
Abstract
Over the past few years, great progress has been made in the development of high-affinity adenosine A(1) and/or A(2A) receptor antagonists-promising agents for the potential treatment of Parkinson's disease. Unfortunately, many of these compounds raise structure-related concerns. The present study investigated the effect of ring closures on the rA(1)/A(2A) affinity of compounds containing a highly reactive alpha,beta-unsaturated carbonyl system, hence providing insight into the potential of heterocycles to address these concerns. A total of 12 heterocyclic compounds were synthesised and evaluated in silico and in vitro. The test compounds performed well upon qualitative assessment of drug-likeness and were generally found to be free from potentially problematic fragments. Most also showed low/weak cytotoxicity. Results from radioligand binding experiments confirm that heterocycles (particularly 2-substituted 3-cyanopyridines) can replace the promiscuous alpha,beta-unsaturated ketone functional group without compromising A(1)/A(2A) affinity. Structure-activity relationships highlighted the importance of hydrogen bonds in binding to the receptors of interest. Compounds 3c (rA(1)K(i) = 16 nM; rA(2A)K(i) = 65 nM) and 8a (rA(1)K(i) = 102 nM; rA(2A)K(i) = 37 nM), which both act as A(1) antagonists, showed significant dual A(1)/A(2A) affinity and may, therefore, inspire further investigation into heterocycles as potentially safe and potent adenosine receptor antagonists.Keywords
Funding Information
- North-West University
This publication has 100 references indexed in Scilit:
- Adenosine and its receptors as therapeutic targets: An overviewSaudi Pharmaceutical Journal, 2013
- Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's diseasePharmacology & Therapeutics, 2011
- Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studiesBiochimica et Biophysica Acta (BBA) - Biomembranes, 2011
- Recent developments in adenosine receptor ligands and their potential as novel drugsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2011
- International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An UpdatePharmacological Reviews, 2011
- Adenosine receptors as drug targetsExperimental Cell Research, 2010
- Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected DiseasesChemMedChem, 2008
- Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockadePurinergic Signalling, 2005
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973